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Elevated expression of a minor isoform of
ANK3 is a risk factor for bipolar disorder
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Robert Karlsson 10, Jie Song10, Marcella Rietschel 11, Markus M. Nöthen8,9, Andreas J. Forstner 7,8,9,12,
Per Hoffmann7,8,9,13, Christina M. Hultman10, Mikael Landén10,14, Sven Cichon7,8,9,15, Thomas Werge5,6,16,
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Abstract
Ankyrin-3 (ANK3) is one of the few genes that have been consistently identiﬁed as associated with bipolar disorder by
multiple genome-wide association studies. However, the exact molecular basis of the association remains unknown. A
rare loss-of-function splice-site SNP (rs41283526*G) in a minor isoform of ANK3 (incorporating exon ENSE00001786716)
was recently identiﬁed as protective of bipolar disorder and schizophrenia. This suggests that an elevated expression
of this isoform may be involved in the etiology of the disorders. In this study, we used novel approaches and data sets
to test this hypothesis. First, we strengthen the statistical evidence supporting the allelic association by replicating the
protective effect of the minor allele of rs41283526 in three additional large independent samples (meta-analysis p-
values: 6.8E–05 for bipolar disorder and 8.2E–04 for schizophrenia). Second, we conﬁrm the hypothesis that both
bipolar and schizophrenia patients have a signiﬁcantly higher expression of this isoform than controls (p-values:
3.3E–05 for schizophrenia and 9.8E–04 for bipolar type I). Third, we determine the transcription start site for this minor
isoform by Paciﬁc Biosciences sequencing of full-length cDNA and show that it is primarily expressed in the corpus
callosum. Finally, we combine genotype and expression data from a large Norwegian sample of psychiatric patients
and controls, and show that the risk alleles in ANK3 identiﬁed by bipolar disorder GWAS are located near the
transcription start site of this isoform and are signiﬁcantly associated with its elevated expression. Together, these
results point to the likely molecular mechanism underlying ANK3´s association with bipolar disorder.
Introduction
Bipolar disorder (BD) is a severe psychiatric pathology
with a lifetime prevalence rate of 1–2%1. Although clearly
polygenic in nature, BD’s high heritability has enabled
well-powered genome-wide association studies (GWAS)
to reveal part of the genetic architecture of the disorder by
identifying common genetic variants that contribute to
BD risk2. However, most associated variants are located in
non-coding regions and are typically, but not always3,
difﬁcult to interpret functionally. Thus, although asso-
ciated variants may provide relatively strong evidence of a
gene’s implication in the etiology, they typically shed little
light on the underlying molecular mechanisms4,5.
The case of the ANK3 gene (encoding ankyrin-G)
illustrates this well. It was the ﬁrst gene to be implicated
in a BD GWAS study6 and the association has been
conﬁrmed by multiple subsequent studies7–10, yet it
remains unclear which speciﬁc gene isoform mediates the
association, whether it is a lowered or elevated level of
functional protein which is a risk factor, or in which cell
type the relevant isoform is expressed.
Ankyrin-G is a large scaffolding adapter protein con-
sisting of two major domains: the ankyrin repeats which
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bind membrane proteins, and the ZU5 and UPA domains
which bind β-spectrin11,12. It has several alternatively
spliced exons, the largest of which has historically been
referred to as the “neuronal” exon and can be spliced in
three different ways11, resulting in big differences in total
protein mass (Fig. 1a). Different versions of these large
isoforms have been detected in neurons at the nodes of
Ranvier13, the axon initial segment and dendritic
spines13, and in oligodendrocytes at the paranodal axo-
glial junction14,15 (Fig. 1c). There are also other smaller
alternatively spliced exons (Fig. 1b) and the RefSeq
database lists ﬁve transcripts16, but the Ensembl data-
base17 and our own data suggest that this is not an
exhaustive list.
A
B
C
Fig. 1 ANK3 gene and protein structure. a Domain structure of the main isoforms of the Ankyrin-G protein with an orientation that matches the
exonic structures in b and with the position of the “little” exon (ENSE00001786716) highlighted. The term “neuronal” exon is historical and perhaps a
misnomer since recent data suggests that the short form of the “neuronal” exon is expressed in oligodendrocytes. b Summary of the exonic structure
of ANK3 based on the ﬁve transcripts in the RefSeq database. Gray shading between a and b depicts the exon to domain mapping. c ANK3’s
interaction partners at the node and paranode in the central nervous system14,45,46. Cntn contactin, Caspr contactin-associated protein, NF
neurofascin, Nav voltage-gated sodium channel, 4.1B protein 4.1B. Little exon in pink, medium exon in green
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We recently identiﬁed, in one of these alternatively
spliced exons (Ensembl exon ID: ENSE00001786716), a
rare loss-of-function splice-site variant (rs41283526*G),
which is strongly protective of both BD and schizophrenia
(SCZ)18. We name this exon the “little” exon in reference
to its short length (Fig. 1b). The variant has a large and
statistically signiﬁcant effect size, but probably only plays
a minor role in the genetic architecture of the disease,
since its allelic frequency is very low (1–2% in European
populations and unobserved in Asian or African popula-
tions)18. However, it does provide valuable insight into the
molecular mechanism since a protective loss-of-function
suggests that an elevated expression of this speciﬁc gene
isoform may be a risk factor.
The present study has four tightly related aims. First, to
further test the protective effect of the loss-of-function
allele of rs41283526 in new independent samples to better
estimate the odds ratio. Second, to directly test whether
the expression of the ANK3 transcript incorporating exon
ENSE00001786716 is elevated in cases. Third, to deter-
mine the transcription start site (TSS) and cell-type spe-
ciﬁcity of this isoform. And, fourth, to investigate the
relationship between the current genome-wide associated
SNPs and the expression of this isoform.
Materials and methods
Association replication and meta-analysis
In the present study, we performed allelic association
tests for rs41283526 in seven independent samples and a
meta-analysis. Three of these samples were used in our
previous work18, while four of them are new.
The samples from previous work are Norwegian (BD
and SCZ) and Swedish (BD). The Swedish BD data is used
unchanged (2286 cases, 5412 controls), but the Norwe-
gian samples are a merging of exome chip and TaqMan
genotyped data sets. As a result, we have one Norwegian
BD data set (504 cases), one Norwegian SCZ data set (411
cases), and one Norwegian control data set (369 controls).
We set two requirements for the new samples: (1)
rs41283526 needs to be present at as high a frequency as
possible, thus we focus on North-European samples
where the allele frequency ranges between 1.2 and 3.1
percent (Table S2); (2) samples must be directly geno-
typed for this functional variant as the quality of impu-
tation of SNPs in this frequency range is poor19. We
identiﬁed four cohorts that fulﬁll these criteria: Danish BD
(193 cases and 696 controls), German BD (895 cases and
2367 controls), Swedish SCZ (4822 cases and 6088 con-
trols), and Danish SCZ (1872 cases and 1091 controls). All
studies obtained informed consent from participants and
obtained approval of protocols and procedures from their
local Ethics Committees (Sample details in Table S3).
We used PLINK20 to test for Hardy–Weinberg equili-
brium (Table S1) and for allelic association on all samples
(–ﬁsher option). Fisher one-tailed tests were performed in
R (Table 1A). We did not perform genotypic tests because
of the low frequency of the SNP.
In addition to being analyzed separately, the four new
samples presented here were combined with the three
samples from previous work to give a total of seven allelic
association tests (four BD and three SCZ) and used in a
meta-analysis. We use METAL21 to calculate a signed Z-
score test: Z-scores for each allele are combined across
samples in a weighted sum, with weights proportional to
the square-root of the sample size for each study. We used
PLINK20 to calculate both ﬁxed-effect and random-effect
models (--meta-analysis option). Heterogeneity statistics
were computed in PLINK (Q and I2) and METAL (I2
heterogeneity test).
BrainSpan developmental transcriptome
We analyzed ANK3 exon expression in the develop-
mental transcriptome data set from BrainSpan22. This is a
RNA-seq data set from the brains of 38 individuals with
ages ranging from 5 weeks post-conception to 40 years
old where tissue samples were taken from 8 to 16 struc-
tures of each brain. This data set provides a quantitation
of expression levels of each exon of ANK3 in each
structure at different points in human brain development.
We plotted this data in Fig. 3a and performed a Wilcoxon
one-sided test of higher expression of the “little” exon in
individuals aged 11 or older (vs. individuals aged 0 to 10
years old) in 16 different brain regions (Table S4).
Differential expression in blood
A total of 919 blood samples for gene expression ana-
lysis were collected (Table S5) using Tempus Blood RNA
Tubes (Life Technologies Corporation, Carlsbad, CA,
USA). RNA extraction and cDNA generation was per-
formed as described in detail in the supplementary
materials. Expression of the alt-2 splice pattern (Fig. 1b)
was measured by RT-qPCR on the ABI PRISM 7900HT
Real-Time PCR System (Life Technologies Corporation,
Carlsbad, CA, USA), using a SYBR green assay (see Sup-
plementary materials). We performed one-sided t test of
higher expression in cases than controls for each of the
diagnostic groups (both including and excluding carriers
of rs41283526*G) (Table 2; Fig. 3b). Diagnostic groups are
healthy controls (CTRL), schizophrenia broad deﬁnition
(SCZ), BD type I (BDI), BD type II (BDII), and major
depression and psychosis not otherwise speciﬁed (MIX).
ANK3 isoforms in human brain
Brain regions expressing alt-2
There are three splice patterns in the region of interest
(genetic ROI), as illustrated in Fig. 1b: (1) alt-0 which
incorporates neither the “little” nor the “medium”; (2) alt-
1 that incorporates the “medium” exon; (3) alt-2 which
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incorporates both the “medium” and the “little” exon. In
order to determine whether there are differences between
brain regions in the expression of the different splice
patterns, we obtained total RNA pools from seven dif-
ferent brain regions (Clontech Laboratories Inc, Moun-
tain View, California) and generated cDNA (Table S6).
We designed primers in the “5′ constitutive” exon and the
“3′ constitutive” exon (Fig. 1b) and we performed a PCR
ampliﬁcation of the region containing the “little” exon.
The ampliﬁed products were subjected to capillary elec-
trophoresis on the 3730xl DNA Analyzer (Applied Bio-
systems, Foster City, California) and splice patterns were
detected on the GeneMapper 5 software (Applied Bio-
systems). The data clearly show that the alt-1 and alt-2
splice patterns are more highly expressed in cerebral
cortex and corpus callosum (Table S7).
Active transcription start sites
We next sought to determine which are the active
transcription start sites in these two tissues where alt-1
and alt-2 are expressed. We generated full-length cDNA
from 1 µg of total RNA, using the SMARTer® PCR cDNA
Synthesis Kit (Takara Bio USA, Inc., Mountain View, CA,
USA). Target-speciﬁc products were generated directly
from ﬁrst-strand cDNA products, using the QIAGEN
LongRange PCR Kit (QIAGEN, Hilden, Germany) and
four different forward primers placed in each of the four
ﬁrst exons of ANK3 (Fig. 1b) and one common reverse
primer in the 3’ UTR. Finally, peak detection was per-
formed with the Agilent DNA 12000 Kit on the 2100
Bioanalyzer system (Agilent Technologies, Santa Clara,
CA, USA).
We obtained no ampliﬁcation from the TSSes of
NM_001204403 or NM_001149 and multiple peak sizes
in the expected ranges for NM_001204404 and
NM_020987 (Table S8). The large differences in product
size (varying from 6 to 12 kbp) are due to the alternative
splicing of the large “neuronal” exon (Fig. 1a).
Paciﬁc Biosciences sequencing
We aimed to determine from which TSS the different
splice patterns of the genetic ROI are expressed and their
relative abundance (in corpus callosum and cerebral
cortex). Since we intended to determine the exonic
structures while preserving relative abundances, we
avoided length ampliﬁcation bias by generating shorter
ampliﬁcation products: we use the full-length cDNA
previously generated and performed target-speciﬁc PCR
using the forward primers in the ﬁrst exon of
NM_001204404 and NM_020987 (as these are the active
TSSs) and a reverse primer three exons downstream of
the ROI (rather than in the 3’ UTR). For each brain
region, the two ampliﬁcations were pooled on equal
volumes and sample preparation for Paciﬁc Biosciences
sequencing was performed with the SMRTbell Template
Prep Kit 1.0 followed by sequencing on one ﬂow cell of
the Paciﬁc BioSciences RS II (Menlo Park, CA, USA). We
obtained ~700k subreads for each brain region library
(Table S9 and S10).
We removed any reads that were not in the expected
size range of 2.7 to 3.3 kbp and where mean read quality
was below 85 percent. We determined the exonic content
of each read by searching for the sequence of the exons of
interest using the BBDUK software (http://jgi.doe.gov/
data-and-tools/bbtools/) with kmer length of 18 bp and
edit distance of 2 (necessary because of the high error rate
in Paciﬁc Biosciences data). In both brain regions, there
were a few dominant splice patterns present at 1% or
more and a large number present at <1%. Of the splice
patterns present at <1%, some were due to a failure to
correctly detect an exon sequence due to the high error
rate of the SMRT system, whereas others may reﬂect
molecules that are present at very low concentrations. For
any splice pattern present in one of the brain regions at
1% or more, we summarized the percentage of subreads
corresponding to this pattern in each of the brain regions
(Fig. 4a).
Effect of SNPs of interest on expression
We wished to determine whether there was any corre-
lation between 28 SNPs of interest and the expression
measures of the “little” exon in blood. We deﬁned SNPs of
interest as the 22 SNPs that were genome-wide signiﬁcant
in the PGC BD GWAS study7 as well as the SNP with the
largest OR in the same study (rs16914810), rs41283526,
and four other SNPs that are in proximity to it and in
strong LD with it. We obtained summary statistics for the
PGC BD GWAS from the Ricopili tool (https://data.
broadinstitute.org/mpg/ricopili/). Norwegian samples
were directly genotyped and imputed as previously
described23. Haplotypes were inferred from the 1167
genotyped Norwegian samples using Haploview24,25, and
haploblocks were determined using the 4 gametes rule26
(with the requirement that the 4th gamete be observed at
a frequency above 1%). D’ and r2 were computed using
PLINK20 with –ld option for 1167 samples and plotted in
R (Fig. 4c).
In the 705 Norwegian samples for which we had both
genotypes and measures of expression of alt-2 in blood,
we computed one-sided Wilcoxon tests of higher
expression of the little exon in minor allele carriers vs.
non-carriers for each of the SNPs of interest (Table 3). We
used the Wilcoxon test because of the low frequency of
the minor alleles at these sites. We also performed the
same test with the carriers of rs41283526*G excluded
from the analysis (reducing the number of samples to 691)
in order to exclude the known strong effect of this variant
on the expression of the “little” exon18.
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Results
Association replication and meta-analysis
The sample-speciﬁc allelic association tests for
rs41283526*G have protective ORs in all four samples: 0.49
(BD Denmark), 0.51 (BD Germany), 0.81 (SCZ Sweden),
0.64 (SCZ Denmark). In our previous work, we established
that rs41283526*G has a protective effect, thus the one-
tailed Fisher test is the relevant metric for replication and it
shows that the association is replicated in three of the four
new independent samples: the Germany BD (p-value=
2.1E–02), Sweden SCZ (p-value= 3.3E–02), and Denmark
SCZ (p-value= 5.0E–02) samples (Table 1A).
All three meta-analysis two-sided tests (ﬁxed effects,
random effects, and weighted Z-score) were all nominally
signiﬁcant in both BD and SCZ groups (Table 1B). Het-
erogeneity metrics show that there is considerable het-
erogeneity between the samples, thus indicating that the
random effects model probably provides the most reliable
estimate of the odds ratio BD (0.5), SCZ (0.53), and 0.54
(BD & SCZ).
Fig. 2 OR conﬁdence intervals for rs41283526 in bipolar disorder and schizophrenia. Odds ratios’ 95% conﬁdence intervals for two-sided χ2
tests and ﬁxed-effect meta-analysis. Individual studies (black) and meta-analyses (red). * Indicates new replication data sets. Numbers of cases/
controls in parenthesis
Table 1A Allelic association tests for rs41283526*G performed in PLINK and R
Samples Numbers Allele frequency p-value
Cases Controls Cases Controls OR Std. err. Fisher (2-sided) Fisher (1-sided)
BD Norway 504 369 0.008 0.031 0.25 0.41 3.6E–04 2.8E–04
Sweden 2286 5412 0.012 0.016 0.72 0.16 4.0E–02 2.1E–02
Denmarka 193 696 0.008 0.016 0.49 0.62 3.3E–01 1.7E–01
Germanya 895 2367 0.006 0.012 0.51 0.33 4.0E–02 2.1E–02
SCZ Norway 411 369 0.005 0.031 0.15 0.54 5.4E–05 4.6E–05
Swedena 4822 6088 0.014 0.018 0.81 0.11 6.6E–02 3.3E–02
Denmarka 1872 1091 0.009 0.014 0.64 0.25 8.7E–02 5.0E–02
aIndicates new replication data sets
Table 1B Meta-analysis for rs41283526*G performed in PLINK and METAL
Meta-analysis Fixed effects Random effects Weighted Z-score Heterogeneity
OR p-value OR p-value Direction p-value Q I2 p-value
BD 0.60 1.2E–04 0.50 5.1E–03 ---- 6.8E–05 0.10 52.20 9.9E–02
SCZ 0.74 2.5E–03 0.53 5.4E–02 --- 8.2E–04 0.01 79.10 8.4E–03
In the weighted Z-score analysis, weights are set as recommend to the effective sample size: Neff= 4/(1/Ncases+ 1/Nctrls)
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Figure 2 shows the conﬁdence intervals for the ORs of
both the individual samples and the three different meta-
analyses. The protective effect of the variant is evident
with the upper bound of all conﬁdence intervals at or
below 1, with the exception of the smaller Danish BD
sample.
BrainSpan developmental transcriptome
Most exons of ANK3 are expressed at all development
stages and in all brain regions whereas the “medium” exon
ramps in expression through childhood and the “little”
exon is switched on in early adolescence18. A Wilcoxon
test of higher expression of the “little” exon in those over
10 years old across all brain regions was highly signiﬁcant
(p-value= 1.386e−08). In order to determine whether
this temporal pattern is consistent between brain regions,
we plot the expression level of the little exon in infants
and children vs. adolescents and adults for each brain
region (Fig. 3a). This shows that in 10 of 16 regions the
expression in those under 10 years old has a median of 0
while it is greater than zero for those older than 10 years
old. Formal testing for differential expression (Table S4)
shows that for six of these regions, the higher expression
in adolescents and adults is nominally signiﬁcant at 5%
(three remain signiﬁcant after correction for multiple
testing). This conﬁrms the unique developmental
expression pattern of the “little” exon.
Differential expression in blood
Expression levels of the alt-2 splice pattern in blood
cells were compared across diagnostic groups (Fig. 3b).
Carriers of the rs41283526*G allele are concentrated in
the control group and have an expression mostly in the
lowest percentile, graphically demonstrating the protec-
tive effect of the loss-of-function allele. Mean expression
is statistically signiﬁcantly higher in the SCZ and BDI
groups, whereas it is not for the BDII and MIX groups
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Fig. 3 Alt-2 splice pattern expression at different development stages and by diagnosis. a Expression of the “little” exon in 16 different brain
regions for individuals aged 0–10 years old (gray) and individuals aged 11 and older (red) from the BrainSpan database. The median is indicated by a
horizontal black bar, but is not always visible as the median is zero in several brain regions. Brain region abbreviations and formal statistical tests of
differential expression between age groups in table S4. b Alt-2 expression in blood measured by qPCR in the Norwegian sample. Carriers of the minor
allele at rs41283526 in red, non-carriers in black. Mean for each diagnostic group (black horizontal bar). See Table 2 for statistical tests
Table 2 Test of elevated expression of alt-2 splice pattern
in blood by diagnostic group
Genotype Group Samples Expression FC t test
(count) (mean) (p-value)
All genotyped samples
CTRL 269 0.982 NA NA
MIX 123 1.007 1.026 1.5E–01
SCZ 309 1.062 1.082 3.3E–05
BDNOS 19 1.061 1.081 1.3E–01
BD I 140 1.064 1.084 9.8E–04
BDII 59 0.946 0.964 8.4E–01
BDI & SCZ 449 1.063 1.083 7.6E–06
Excl. carriers of rs41283526*G
CTRL 256 1.004 NA NA
MIX 120 1.014 1.010 3.3E–01
SCZ 309 1.062 1.058 1.3E–03
BDNOS 19 1.061 1.058 2.1E–01
BD I 138 1.073 1.069 3.6E–03
BDII 59 0.946 0.943 9.5E–01
BDI & SCZ 447 1.065 1.062 2.8E–04
One-sided tests of elevated expression in cases vs. controls (for each diagnostic
group)
FC: fold change (diag/ctrl)
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(Table 2). Crucially, these tests remained signiﬁcant when
we excluded carriers of rs41283526*G, thus indicating
that the differential expression of the alt-2 splice pattern is
not solely driven by rs41283526*G.
Figure 3b shows that the SCZ and BDI groups have an
excess of very high expressors relative to the control
group, and we therefore performed a Fisher association
test between high expression (deﬁned as above 1.5)
and diagnostic group. We ﬁnd that the BDI group
has the highest odds ratio at 4.9 (p-value= 2.0E–03)
(Table S11).
ANK3 isoforms in human brain
We established that the alt-2 splice pattern is most
strongly expressed in the corpus callosum by PCR
ampliﬁcation of cDNA generated from total RNA of seven
different regions of human brain (Table S7). The RefSeq
models show the alt-2 splice pattern being expressed from
the TSS of NM_001204404 (Fig. 4b). However, because
several kilobases of constitutive exons separate the genetic
ROI from the TSS, we considered it necessary to use long
read sequencing to clearly establish from which TSS each
of the alternative splice patterns were expressed.
Table 3 Summary GWAS statistics from the PGC bipolar disorder GWAS at 28 loci and differential expression of the
“little” exon by genotype
# Single nucleotide polymorphism PGC 2011 BD GWAS Norwegian sample (eQTL test)
dbSNP RSID Position (hg19:
chr10)
Major allele Minor allele G1K European MAF P-value OR (minor) MAF All samples
(n=705)
Excl.carriers of
rs41283526*G
(n=691)
FC p-value FC p-value
1 rs2288359a 61902023 C T 0.059 1.2E–01 1.09 0.064 1.09 5.3E–04 1.08 1.2E–03
2 rs41283526a 61905727 A G 0.016 3.6E–04b 0.25b 0.013 0.54 1.2E–08 NAc NAc
3 rs12357972a 61907907 T C 0.048 5.5E–03 1.16 0.051 1.08 3.0E–03 1.07 5.8E–03
4 rs16914810 61913414 T C 0.047 2.1E–02 1.98 0.05 1.08 2.0E–03 1.07 4.0E–03
5 rs2393614a 61915955 C T 0.319 9.6E–02 1.05 0.358 1.04 2.5E–02 1.02 8.0E–02
6 rs10509125a 61926866 A C 0.394 2.5E–02 1.06 0.429 1.08 4.9E–05 1.06 6.3E–04
7 rs10761473 62060382 C G 0.078 5.6E–09 1.36 0.057 1.01 3.9E–01 1.00 5.1E–01
8 rs10509129 62071041 G T 0.047 5.8E–09 1.36 0.041 1.04 1.3E–01 1.03 1.9E–01
9 rs1380459 62097331 C T 0.070 3.3E–09 1.36 0.052 1.03 1.2E–01 1.02 1.8E–01
10 rs10994308 62098952 G A 0.070 3.8E–09 1.36 0.052 1.03 1.2E–01 1.02 1.8E–01
11 rs10821736a 62105053 C T 0.070 1.3E–09 1.36 0.052 1.04 8.6E–02 1.03 1.3E–01
12 rs10821745a 62136206 T G 0.069 2.3E–09 1.35 0.054 1.04 5.7E–02 1.03 9.2E–02
13 rs10994322a 62136279 C T 0.069 6.7E–09 1.35 0.054 1.04 5.7E–02 1.03 9.2E–02
14 rs4948412 62146576 T C 0.068 5.3E–09 1.35 0.054 1.04 5.7E–02 1.03 9.2E–02
15 rs3808943 62151015 C T 0.069 4.7E–09 1.35 0.056 1.04 5.8E–02 1.03 9.4E–02
16 rs10821748 62152938 G C 0.071 4.4E–08 1.32 0.054 1.04 5.7E–02 1.03 9.2E–02
17 rs12416380 62156154 A G 0.069 7.5E–09 1.35 0.054 1.04 5.7E–02 1.03 9.2E–02
18 rs4948417a 62161618 A G 0.068 5.5E–09 1.35 0.054 1.04 5.7E–02 1.03 9.2E–02
19 rs10994336a 62179812 C T 0.073 4.0E–09 1.35 0.052 1.04 9.8E–02 1.03 1.5E–01
20 rs10994338a 62181128 C T 0.073 6.7E–09 1.34 0.052 1.04 9.8E–02 1.03 1.5E–01
21 rs9633553 62274737 T G 0.075 5.5E–10 1.35 0.054 1.05 7.0E–02 1.04 1.1E–01
22 rs10994397a 62279124 C T 0.075 5.5E–10 1.35 0.054 1.05 7.0E–02 1.04 1.1E–01
23 rs12412135 62282834 C T 0.094 4.2E–08 1.27 0.074 1.05 1.5E–02 1.05 1.9E–02
24 rs1938540 62294814 C T 0.079 1.9E–09 1.33 0.054 1.06 2.5E–02 1.05 4.3E–02
25 rs10821792a 62298616 C T 0.079 2.0E–09 1.32 0.054 1.06 2.5E–02 1.05 4.3E–02
26 rs1938526 62300383 A G 0.079 1.9E–09 1.32 0.054 1.06 2.5E–02 1.05 4.3E–02
27 rs10994415 62322034 T C 0.074 7.0E–10 1.31 0.075 1.04 8.1E–02 1.03 1.4E–01
28 rs2154393 62326687 C T 0.074 3.7E–09 1.29 0.076 1.04 7.2E–02 1.03 1.3E–01
Fold change (FC) is the ratio of the mean “little” exon expression for minor allele carriers to the mean for non-carriers. Tests are one-sided Wilcoxon test of higher
expression of the little exon in minor allele carriers vs. non-carriers (with the exception of rs41283526, where we test lower expression in carriers)
p-values are uncorrected for multiple testing and sites signiﬁcant at 5% are highlighted in bold
Samples used in the differential expression tests (eQTL test) are either all samples for which genotypes and expression are available (n= 705) or excluding those
carrying the minor allele at rs41283526 (n= 691)
MAF in Norwegian sample is based on 1167 genotyped samples. Horizontal lines delineate haploblocks as determined by four gametes method on the Norwegian
sample
MAF minor allele frequency, G1K 1000 genomes project (503 European individuals in G1K)
aIndicates directly genotyped SNP (as opposed to imputed)
bSNP minor allele frequency was too low to be genotyped or imputed with conﬁdence in PGC GWAS. Instead, we include here the results for the Norwegian BD
sample for comparison with the PGC ORs
cNot available because of the exclusion of samples carrying rs41283526*G
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Fig. 4 Expression of the ANK3 isoforms and its relationship to the genetic risk for bipolar disorder. a Summary statistics of isoform expression
levels in two different brain regions by Paciﬁc Biosciences single-molecule real-time sequencing. Percentages do not sum to 100% due to the high
number of very low frequency isoforms not represented in the ﬁgure. b ANK3 transcript models as listed by the RefSeq database. Note that our long
read data summarized in a show the RefSeq models to be incomplete and possibly incorrect. c Summary statistics from the PGC Bipolar Disorder
GWAS (2011) in the ANK3 region. Odds ratios for the minor allele with genome-wide signiﬁcantly associated SNPs in red (p-value <= 5.0E–08).
Rs41283526 odds ratio from Norwegian sample added to plot (in blue) for consistency with lower panels. r2 and D’ were computed from the
Norwegian sample including all samples irrespective of diagnostic group. Haploblocks were computed in Haploview: signiﬁcant SNPs from Table 3
highlighted in bold and minor haplotypes with majority of signiﬁcant SNPs in black rectangles. Haplotype frequencies are highlighted in italics.
Haplotypes are connected by a thin line if >1% and by a thick line if greater than 10%
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We determined that only the TSSes of NM_001204404
and NM_020987 are active in the seven brain regions that
we tested (Table S8). Our Paciﬁc Biosciences sequencing
data from human brain identiﬁed ﬁve isoforms tran-
scribed from these TSSes (Fig. 4a), one of which incor-
porates the alt-2 splice pattern and is transcribed from the
TSS of NM_020987 (at 62.2 Mbp). The TSS of
NM_020987 is dominant in the corpus callosum. The TSS
of NM_001204404, on the other hand, is clearly dominant
in the cerebral cortex. In terms of the genetic ROI, alt-0 is
clearly dominant in cerebral cortex (82%), whereas alt-1 is
the dominant isoform in corpus callosum (84%). As to alt-
2, it is only detected in corpus callosum and transcribed
from the NM_020987 TSS.
Differential expression and bipolar disorder associated
SNPs
We have demonstrated that (1) rs41283526*G has
protective and statistically signiﬁcant effect in multiple
independent samples; (2) BD and SCZ patients have
elevated expression of the alt-2 splice pattern in blood
(even when excluding the effect of rs41283526*G); and
(3) the alt-2 splice pattern is transcribed from the TSS of
NM_020987 which is the dominant TSS in corpus cal-
losum. We then sought to establish how these results
relate to the existing GWAS results (Fig. 4c) and in
particular to the PGC BD GWAS7. There are 22
genome-wide signiﬁcant SNPs in the PGC BD pheno-
type association study located in ANK3. They are all in
strong linkage disequilibrium, with an OR of ~1.3 and
located within ~100 kbp of the TSS of NM_020987.
There are no signiﬁcant SNPs upstream of the TSS of
NM_001204404, which suggests that the signiﬁcant
SNPs may control the regulation of an ANK3 isoform
transcribed from the TSS of NM_020987. For each of 28
SNPs (22 from PGC plus the SNP with the highest OR,
rs16914810, and 4 SNPs in strong LD with and proxi-
mity to rs41283526), we tested for differential expres-
sion (DE) of alt-2 in carriers vs. non-carriers of the
minor allele (higher expression in carriers for all sites
except rs41283526*G where we test for lower expres-
sion). As expected, the protective allele rs41283526*G
stands out with a highly signiﬁcant lowered expression
(Table 3). The minor alleles of the other 27 sites, which
confer risk of BD, are associated with higher expression
of alt-2 (8 of these at 5% signiﬁcance or lower). This is in
complete concordance with the protective effect of
rs41283526*G, which lowers alt-2 expression (Table 3).
This result remains signiﬁcant when we eliminate any
possible effect of rs41283526*G on the DE test results by
excluding carriers of rs41283526*G (Table 3). These 28
tests are not independent as the minor alleles are pre-
sent on only two different haplotypes (Fig. 4), we
therefore do not correct for multiple testing.
Four of the signiﬁcant SNPs are located close to the
“little” exon whereas four are upstream of the TSS. We
therefore investigate the LD structure of the region to
establish its inﬂuence on these results (Fig. 4c). This
shows that there are two independent signals (one from
the genetic ROI region and one from the TSS) and these
are independent of rs41283526. The PGC GWAS risk
alleles, that are also signiﬁcantly associated with an
increased expression of alt-2, are located on the minor
haplotypes in different blocks: haplotype 03 in block 1
(ROI) and haplotype 02 in block 3 (TSS). Interestingly,
these two minor haplotypes do not form part of the same
haplotype across blocks as can be seen from the haplo-
types in Fig. 4c and the very low r2 and D’ between the tag
SNPs 03 (rs12357972) and 26 (rs1938526). Moreover,
these risk haplotypes are independent of rs41283526*G
which is located on its own haplotype 05 in block 1 which
extends into the major haplotype 01 in block 02 and 03.
We did also perform a classical conditional regression
analysis for rs41283526 for the BD, SCZ, and BD & SCZ
diagnostic groups in the Norwegian sample (unpublished)
as a second approach to studying the relationship between
the BD GWAS SNPs and rs41283526. However, due to
the modest sample size, none of the genome-wide asso-
ciated hits from PGC BD GWAS showed signiﬁcant
association in the logistic regression (p-values > 0.05 in all
three diagnostic groups), so the logistic regression with
conditioning on rs41283526 was not informative. This
lead us to focus on the differential expression results
presented above, where informative results were obtained.
Discussion
BD is a polygenic, and most probably also a hetero-
geneous disease, making it difﬁcult to isolate and char-
acterize the complex underlying molecular mechanisms5.
Here, we present multiple statistically signiﬁcant ﬁndings
of the involvement of ANK3 at the DNA and RNA levels,
which are consistent with each other and with existing
GWAS data, and inform on the underlying molecular
genetic mechanisms of BD.
The protective effect of rs41283526*G
We report replication of our previous ﬁndings, con-
ﬁrming the protective effect of rs41283526*G against BD
and SCZ despite the fact that it is difﬁcult to achieve
statistical signiﬁcance for low frequency SNPs27. In par-
ticular, six of seven individual cohort one-tailed tests are
signiﬁcant at 5% signiﬁcance (Table 1A). In addition, the
meta-analyses (weighted Z-score) for BD (p-value:
6.8E–05) and SCZ (p-value: 8.2E–04) are both signiﬁcant.
The effect sizes reported, although modest in the con-
text of statistical testing, are strong in the context of the
BD GWAS literature. Even the weakest effect size
observed in our data (Swedish OR= 0.72) rivals that of
Hughes et al. Translational Psychiatry  (2018) 8:210 Page 9 of 12
the strongest risk effects previously reported6,7, while the
Norwegian effect (OR= 0.25) is several times stronger.
However, the range of ORs is wide for BD [0.25,0.72] and
for SCZ [0.15,0.81], thus making it difﬁcult to estimate the
true strength of the protective effect. There are two fac-
tors that are most likely to be driving the variance in ORs:
the low frequency of rs41283526*G (Table 1A) and study
heterogeneity, which tends to affect the analysis of com-
plex phenotypes such as mental-health-related diseases28.
However, this variance does not detract from the strong
and statistically signiﬁcant protective effect
The protective effect of a loss-of-function variant may
be somewhat counter-intuitive, because one typically
thinks of loss-of-function as being deleterious. This is
correct when considering a variant in isolation; however,
if one considers the wider genetic context in which other
variation may lead to pathologically high expression
levels, it then becomes clear how a loss-of-function allele
can restore balance. The high-effect size may also be
surprising, but this is explained by the total loss-of-
function of the splice site for the affected allele18. Finally,
it may also seem illogical that dysregulation of a minor
isoform of ANK3 could be the underlying cause of the
gene’s association with the disorder. However, the 50%
change in expression observed in heterozygote carriers18
is as likely to have physiologic effects, as similarly sized
changes to the other more abundant isoforms, because it
is the relative dosage of proteins that is the key.
Expression of the alt-2 splice pattern
Ideally we would have obtained RNA samples from the
brains of the cases and controls that we had genotyped.
For obvious reasons, this was not possible, so we had to
rely on blood samples. We know that the absolute levels
of ANK3 expression are much lower in blood than in
brain. However, as long as rank order of expression is
somewhat maintained (i.e., that a high expressor in brain
does not become a low expressor in blood), then we
expect to be able to detect signiﬁcant differences between
groups, if our main hypothesis is correct.
The mean expression of alt-2 is signiﬁcantly elevated in
SCZ and BDI relative to controls (Fig. 3b) and, crucially,
this is also true when carriers of rs41283526*G are
excluded (Table 2). This indicates that the observed ele-
vated expression of alt-2 is not solely driven by the rare
rs41283526*G allele and that elevated expression is a risk
factor in the general patient population. The concordance
between SCZ and BDI is perhaps not surprising given that
they are the two psychiatric diseases with the highest
genetic correlation29,30 and are both characterized by
psychotic symptoms.
The test of differential expression of alt-2 between those
over and under 10 years old (Brainspan data set) shows
that expression of the isoform begins in adolescence (Fig.
3b; Table S4). This provides further corroborative evi-
dence of this isoform’s central role in the etiology, because
the onset of the ﬁrst hypomanic episode of BD typically
happens in adolescence1 and no other exon of ANK3
shows such a change in expression during post-natal
development according to the BrainSpan database.
The function of the evolutionarily conserved peptide
sequence encoded by the little exon is unknown. How-
ever, available bioinformatic structural data suggests that
the peptide sequence is unstructured linker possibly
containing a linear motif. The most signiﬁcant hit in the
Eukaryotic Linear Motif database31 for the little exon
peptide sequence (GNRCTWYKIPKVQEFTVK) is for an
N-myristoylation site which mediates myristate attach-
ment to an N-terminal glycine residue. In ANK3, this
glycine residue is not N-terminal; however, post-
translational myristoylation is known to typically occur
following a caspase cleavage event resulting in the expo-
sure of the internal glycine residue32. The C-terminal
amino acids of the “medium” exon followed by this gly-
cine residue is a possible match for a caspase cleavage
site33. Further, the extended model of the myristoylation
motif is 17 amino acids long34, which is a close match to
the 18 amino acids of the “little” exon. Interestingly,
myristate attachment to an N-terminal glycine residue
acts as a membrane anchor for some soluble cytoplasmic
proteins32.
Indications of ANK3 isoforms cell-type speciﬁcity
Our long read sequencing of ANK3 transcripts shows
that the RefSeq list is not complete, since it contains only
one of the ﬁve isoforms that we detect, namely the most
abundant isoform in the corpus callosum (alt-1 isoform
with the NM_020987 TSS). Further, RefSeq suggests that
the NM_001204404 isoform incorporates the alt-2 pat-
tern, but our data show only the alt-0 and alt-1 splice
patterns being expressed from this TSS.
The alt-2 splice pattern is incorporated into the isoform
transcribed from the TSS of NM_020987 and is expressed
in the corpus callosum, but not in the cerebral cortex (Fig.
4a). The TSS of NM_020987 is dominant in the corpus
callosum which consists primarily of myelinated axons
but where the cell soma are almost exclusively oligoden-
drocytic35. Thus, our data are consistent with the existing
data obtained by conditional knock-out of ANK3 in
mouse oligodendrocytes14, as they also show that the
NM_020987 TSS is dominant in oligodendrocytes. The
alt-2 splice pattern is not incorporated into the isoforms
transcribed from the TSS of NM_001204404, which is
dominant in the cerebral cortex. Axons in the cerebral
cortex, and particularly the sections in layers I–III have
been shown to not be myelinated36, thus sequence from
this brain region provides a better indication of the RNA
content of neurons. In summary, our results suggest that
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alt-2 is expressed in oligodendrocytes, but probably not in
neurons.
It has previously been hypothesized that BD and SCZ
may be caused by disruption of the myelination pro-
cess37,38. There has been some suggestive evidence of
molecular abnormalities at the nodes of Ranvier39, but
perhaps the most compelling evidence of this comes from
brain imaging data which shows the smaller size of the
corpus callosum in both BD patients and their ﬁrst degree
relatives40,41, and reduced levels of myelin42–44. Our
results indicate that, at least with regards to ANK3’s role
in the etiology of BD, the elevated expression of the alt-2
splice form is most likely occurring in oligodendrocytes
and probably not in neurons, and its protein product may
well be located at the nodes of Ranvier since an ANK3
isoform has been detected on the glial side of the para-
nodes (Fig. 1c)14.
It is important to note that we are not suggesting that
the corpus callosum is necessarily the brain structure
where the pathology originates. Rather it is here that both
the molecular and imaging phenotypes are clearly
detectable due to the high levels of myelinating oligo-
dendrocytes. Myelinated axons are found throughout the
brain and the “little” exon is also detected in most brain
structures after 10 years of age (Fig. 3a), thus our data
provide no strict indication of the brain region in which
the imbalance may be causing the BD behavioral
phenotype.
Relationship with GWAS results
Our analysis of the differential expression of alt-2
between carriers and non-carriers of the PGC GWAS
minor alleles demonstrates complete consistency between
the genotype/phenotype association of the PGC and the
genotype/isoform expression association we present in
Table 3 and Fig. 4b: risk minor alleles from the PGC study
are associated with an elevated expression of alt-2, while
the protective minor allele of rs41283526 is associated
with a halving of alt-2 expression. Further, the haplotype
structure reveals that there are two independent minor
haplotypes raising the expression of alt-2 that are inde-
pendent of rs41283526*G: the minor haplotype 03 in
block 1 (ROI) and the minor haplotype 02 in blocks 2 and
3 (TSS). Interestingly, with the beneﬁt of hindsight, it is
possible to see that the PGC OR plot contains tell-tale
signs of our ﬁndings (Fig. 4c): (1) the PGC signiﬁcant
SNPs frame the TSS of NM_020987 and, (2) the genetic
ROI is almost devoid of SNPs with a neutral OR, while the
rest of the ANK3 gene is dominated by SNPs with ORs of
1.
Conclusion
The loss-of-function allele rs41283526*G has a strong
protective effect against both BD and SCZ that replicates
in six independent samples. It is not itself a major con-
tributing factor to the association of ANK3 with BD (due
to its low frequency), but it strongly suggests that elevated
expression of the ANK3 isoform incorporating exon
ENS00001786716 may be a factor in the pathobiology of
the disorder. Our analysis of human RNA data sets shows
that the available data strongly support this hypothesis
and previous GWAS ﬁndings are also consistent with it.
Further, we provide evidence that the speciﬁc isoform is
most strongly expressed in corpus callosum, which sug-
gests that it may be in oligodendrocytes that the imbal-
ance occurs. We look forward to future studies of the role
of this speciﬁc isoform in myelination and, particularly, in
the formation and maintenance of nodes of Ranvier.
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